Compare Newmont Corporation (NEM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Twist Bioscience Corp — how do they compare? Newmont Corporation trades at $128.63 (market cap $133.91B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Newmont Corporation is far larger — about 15.9× Twist Bioscience Corp's market cap, and Newmont Corporation pays a 0.82% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NEM | TWST | |
|---|---|---|
Market Cap | $133.91B | $8.42B |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $153.10 |
52-Week Low | $78.32 | $24.16 |
Enterprise Value | $130.50B | $8.35B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $127.09, down 0.78% on the day, with strong fundamental performance including a 31.25% net income margin in 2025 and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while recent news highlights production challenges and institutional accumulation. Revenue growth is robust, projected to reach $25.8 billion in 2026.
Outlook remains positive due to high analyst buy ratings (75.68%) and a $133.29 consensus price target, though risks include operational pressures and gold price volatility. The company's liquidity and debt reduction support shareholder returns, including dividends.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
